Skip to main content

Table 1 Clinical characteristics of the population studied

From: Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)

  Background metformin Background sulfonylurea
  + rosiglitazone + sulfonylurea + rosiglitazone + metformin
Participants (n) 176 165 160 167
Age (yr) 57 ± 8 57 ± 8 60 ± 8 58 ± 8
Male (n (%)) 80 (45) 86 (52) 83 (52) 77 (46)
Europid (n (%)) 175 (> 99) 165 (100) 160 (100) 167 (100)
Body weight (kg) 92 ± 17 94 ± 16 86 ± 13 84 ± 16
BMI (kg/m2) 33 ± 5 32 ± 5 31 ± 4 30 ± 5
Time from diabetes diagnosis (yr) 5.7 ± 3.8 5.9 ± 3.6 7.7 ± 5.1 7.1 ± 5.1
HbA1c (%) 7.8 ± 0.6 7.8 ± 0.8 7.9 ± 0.7 8.0 ± 0.8
Fasting plasma glucose (mmol/l) 9.2 ± 2.1 9.7 ± 2.3 10.0 ± 2.4 10.2 ± 2.4
Homeostasis model assessment %S (%) 68 (42, 106) 64 (42, 108) 64 (47, 88) 63 (42, 93)
Hypertension* (n (%)) 145 (82) 138 (84) 139 (87) 141 (84)
Treated with antihypertensive drugs 119 (68) 112 (68) 104 (65) 114 (68)
Ambulatory systolic BP (mmHg)     
   24-hour 132 ± 14 134 ± 16 132 ± 13 132 ± 14
   Day-time 136 ± 14 138 ± 15 135 ± 13 136 ± 14
   Night-time 126 ± 15 128 ± 18 126 ± 14 127 ± 15
Ambulatory diastolic BP (mmHg)     
   24-hour 78 ± 8 78 ± 9 76 ± 8 76 ± 8
   Day-time 81 ± 8 82 ± 10 79 ± 8 79 ± 8
   Night-time 72 ± 9 73 ± 10 71 ± 9 71 ± 9
Ambulatory heart rate (beat/min)     
   24-hour 76 ± 10 75 ± 9 74 ± 11 75 ± 10
   Day-time 81 ± 11 80 ± 10 79 ± 12 78 ± 11
   Night-time 70 ± 9 69 ± 9 68 ± 10 69 ± 9
  1. Number (percent) or mean ± SD, or median (IQR).
  2. *Medical history or average baseline day-time ABPM > 135/85 mmHg